Amgen Inc. $AMGN Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 172,922 shares of the medical research company’s stock after selling 5,981 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Amgen were worth $56,670,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Anfield Capital Management LLC boosted its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in shares of Amgen during the fourth quarter worth $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. Mizuho raised their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Truist Financial raised their price objective on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Citigroup raised their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Barclays initiated coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $356.15.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $324.39 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The business has a 50 day moving average of $348.31 and a two-hundred day moving average of $343.59. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a market cap of $175.07 billion, a P/E ratio of 22.57, a PEG ratio of 3.28 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s dividend payout ratio is currently 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.